Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-23T09:08:47.549Z Has data issue: false hasContentIssue false
  • English
  • Français

Anaphylactic reaction to anakinra in a child with steroid-dependent idiopathic recurrent pericarditis and successful management with canakinumab

Published online by Cambridge University Press:  01 April 2019

Serdar Epçaçan Open the ORCID record for Serdar Epçaçan [Opens in a new window] ,
Sezgin Sahin Open the ORCID record for Sezgin Sahin [Opens in a new window]  and
Ozgur Kasapcopur
Serdar Epçaçan
Affiliation:
Department of Pediatric Cardiology, Van Training and Research Hospital, University of Health Sciences, Van, Turkey
Sezgin Sahin*
Affiliation:
Department of Pediatric Cardiology, Van Training and Research Hospital, University of Health Sciences, Van, Turkey
Ozgur Kasapcopur
Affiliation:
Department of Pediatric Rheumatology, Van Training and Research Hospital, University of Health Sciences, Van, Turkey Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey
*
Author for correspondence: Sezgin Şahin, MD, Department of Pediatric Rheumatology, Van Training and Research Hospital, University of Health Sciences, 65100, Edremit, Van, Turkey. Tel: +90 506 770 57 28; Email: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Conventional algorithm for treatment of pericarditis and prevention of recurrences consists of non-steroid anti-inflammatory drugs and/or colchicine, followed by corticosteroids in resistant patients. Anakinra has emerged as a promising and safe treatment modality for steroid-dependent idiopathic recurrent pericarditis. However, the efficacy and safety of canakinumab, another anti-interleukin-1 agent, has not been assessed up to date. Herein, we present development of an anaphylactic reaction due to anakinra and a successful subsequent treatment with canakinumab for the first time in the literature.

Keywords

Idiopathic recurrent pericarditistreatmentanti-IL 1 agents
Type
Brief Report
Information
Cardiology in the Young , Volume 29 , Issue 4 , April 2019 , pp. 549 - 551
Copyright
© Cambridge University Press 2019 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Lazaros, G, Antonatou, K, Vassilopoulos, D. The therapeutic role of Interleukin-1 inhibition in idiopathic recurrent pericarditis: current evidence and future challenges. Front Med 2017; 4: 78.CrossRefGoogle ScholarPubMed
Brucato, A, Emmi, G, Cantarini, L, et al. Management of idiopathic recurrent pericarditis in adults and in children: a role for interleukin-1 receptor antagonism. Intern Emerg Med 2018; 13: 475–489.CrossRefGoogle Scholar
Imazio, M, Brucato, A, Pluymaekers, N, et al. Recurrent pericarditis in children and adolescents: a multicentre cohort study. J Cardiovasc Med 2016; 17: 707–712.CrossRefGoogle ScholarPubMed
Tarantino, G, Delogu, AB, De Rosa, G, Rigante, D. A possible still role for colchicine in children with idiopathic recurrent acute pericarditis? Intern Emerg Med 2018; 14: 331–332. doi: 10.1007/s11739-018-1997-5 CrossRefGoogle ScholarPubMed
Rodriguez-Gonzalez, M, Ruiz-Gonzalez, E, Castellano-Martinez, A. Anakinra as rescue therapy for steroid-dependent idiopathic recurrent pericarditis in children: case report and literature review. Cardiol Young 2018; 29: 241–243.CrossRefGoogle ScholarPubMed
Brucato, A, Imazio, M, Gattorno, M, et al. Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP randomized clinical trial. JAMA 2016; 316: 1906–1912.CrossRefGoogle ScholarPubMed
Picco, P, Brisca, G, Traverso, F, Loy, A, Gattorno, M, Martini, A. Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease? Arthritis Rheum 2009; 60: 264–268.CrossRefGoogle ScholarPubMed
Sambola, A, Roca Luque, I, Merce, J, et al. Colchicine administered in the first episode of acute idiopathic pericarditis: a randomized multicenter open-label study. Rev Esp Cardiol (Engl Ed) 2019; pii: S1885-5857(18)30496-1. doi: 10.1016/j.rec.2018.11.016 [Epub ahead of print].Google ScholarPubMed
Lazaros, G, Vasileiou, P, Koutsianas, C, et al. Anakinra for the management of resistant idiopathic recurrent pericarditis. Initial experience in 10 adult cases. Ann Rheum Dis 2014; 73: 2215–2217.CrossRefGoogle ScholarPubMed
Finetti, M, Insalaco, A, Cantarini, L, et al. Long-term efficacy of interleukin-1 receptor antagonist (anakinra) in corticosteroid-dependent and colchicine-resistant recurrent pericarditis. J Pediatr 2014; 164: 1425–1431.CrossRefGoogle ScholarPubMed